NorthCrest Asset Manangement LLC Grows Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

NorthCrest Asset Manangement LLC increased its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 395.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 55,025 shares of the company's stock after purchasing an additional 43,930 shares during the quarter. NorthCrest Asset Manangement LLC's holdings in Dr. Reddy's Laboratories were worth $869,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Pinnacle Wealth Planning Services Inc. raised its holdings in Dr. Reddy's Laboratories by 203.4% during the fourth quarter. Pinnacle Wealth Planning Services Inc. now owns 26,744 shares of the company's stock valued at $422,000 after acquiring an additional 17,930 shares during the period. B. Riley Wealth Advisors Inc. grew its stake in shares of Dr. Reddy's Laboratories by 829.5% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 57,350 shares of the company's stock valued at $906,000 after buying an additional 51,180 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Dr. Reddy's Laboratories by 100.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 16,511 shares of the company's stock worth $261,000 after buying an additional 8,262 shares during the period. Vident Advisory LLC boosted its holdings in Dr. Reddy's Laboratories by 535.5% during the 4th quarter. Vident Advisory LLC now owns 151,331 shares of the company's stock valued at $2,390,000 after acquiring an additional 127,518 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Dr. Reddy's Laboratories during the 4th quarter valued at $1,007,000. 3.85% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th.

Dr. Reddy's Laboratories Trading Down 0.3%

Shares of Dr. Reddy's Laboratories stock traded down $0.04 on Friday, hitting $14.71. 1,612,844 shares of the company traded hands, compared to its average volume of 1,484,237. The stock's 50 day moving average price is $13.68 and its 200-day moving average price is $14.01. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89. The company has a market cap of $12.28 billion, a PE ratio of 23.42 and a beta of 0.33.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.02. The firm had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.